Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 07/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, ACAD, and MRUSShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Akero Therapeutics Vaxcyte ADMA Biologics PTC Therapeutics Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Zai Lab ACADIA Pharmaceuticals Merus Akero Therapeutics (NASDAQ:AKRO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment. Do analysts prefer AKRO or CALT? Akero Therapeutics currently has a consensus price target of $82.50, indicating a potential upside of 59.71%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akero Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, AKRO or CALT? Akero Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Which has higher valuation & earnings, AKRO or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-26.49Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is AKRO or CALT more profitable? Akero Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Akero Therapeutics' return on equity of -15.19% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do institutionals & insiders believe in AKRO or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 7.1% of Akero Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor AKRO or CALT? In the previous week, Akero Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Akero Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Akero Therapeutics' average media sentiment score of 0.90 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akero Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral SummaryAkero Therapeutics beats Calliditas Therapeutics AB (publ) on 9 of the 15 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$783.11M$5.50B$9.01BDividend YieldN/A4.84%5.39%4.11%P/E Ratio-21.621.3027.4220.07Price / Sales0.74222.05398.50109.13Price / CashN/A23.4436.1356.90Price / Book37.746.018.015.70Net Income-$43.96M-$27.64M$3.16B$248.47M7 Day PerformanceN/A0.35%2.08%2.92%1 Month PerformanceN/A6.82%4.38%5.77%1 Year Performance1.39%7.77%35.81%21.39% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AKROAkero Therapeutics3.6442 of 5 stars$54.03-0.3%$82.50+52.7%+131.8%$4.32BN/A-27.7130PCVXVaxcyte1.821 of 5 stars$33.25+1.2%$136.50+310.5%-56.3%$4.24BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.1084 of 5 stars$17.87+0.7%$27.67+54.8%+59.1%$4.24B$426.45M21.02530PTCTPTC Therapeutics4.4297 of 5 stars$49.60-1.2%$65.00+31.0%+61.7%$3.98B$806.78M7.621,410Analyst RevisionRYTMRhythm Pharmaceuticals3.8176 of 5 stars$62.13+0.2%$76.62+23.3%+58.1%$3.94B$130.13M-22.11140CYTKCytokinetics4.301 of 5 stars$32.64+0.6%$70.92+117.3%-37.3%$3.87B$19.22M-6.17250Positive NewsKRYSKrystal Biotech4.559 of 5 stars$137.92+4.1%$211.13+53.1%-20.4%$3.83B$290.52M33.15210News CoverageAnalyst RevisionHigh Trading VolumeZLABZai Lab3.4237 of 5 stars$36.01+4.2%$47.37+31.5%+104.3%$3.81B$398.99M-14.461,869Analyst ForecastInsider TradeAnalyst RevisionGap UpACADACADIA Pharmaceuticals4.6965 of 5 stars$22.48-1.0%$27.64+23.0%+34.1%$3.80B$957.80M16.41510MRUSMerus1.8524 of 5 stars$52.74-0.7%$84.64+60.5%+0.5%$3.68B$36.13M-12.9337 Related Companies and Tools Related Companies Akero Therapeutics Alternatives Vaxcyte Alternatives ADMA Biologics Alternatives PTC Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives Krystal Biotech Alternatives Zai Lab Alternatives ACADIA Pharmaceuticals Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
